🇺🇸 GLP-1 medication in United States

FDA authorised GLP-1 medication on 8 November 2023

Marketing authorisations

FDA — authorised 8 November 2023

  • Application: NDA217806
  • Marketing authorisation holder: ELI LILLY AND CO
  • Local brand name: ZEPBOUND (AUTOINJECTOR)
  • Indication: SOLUTION — SUBCUTANEOUS
  • Status: approved

Read official source →

FDA

  • Status: approved

GLP-1 medication in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is GLP-1 medication approved in United States?

Yes. FDA authorised it on 8 November 2023; FDA has authorised it.

Who is the marketing authorisation holder for GLP-1 medication in United States?

ELI LILLY AND CO holds the US marketing authorisation.